Medzone Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 21-06-2024
- Paid Up Capital ₹ 0.50 M
as on 21-06-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.78 M
as on 21-06-2024
- Revenue -18.08%
(FY 2017)
- Profit 16.92%
(FY 2017)
- Ebitda 10.20%
(FY 2017)
- Net Worth -4.94%
(FY 2017)
- Total Assets -7.21%
(FY 2017)
About Medzone Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.78 M.
Chandra Gnanatilakan, Deivasigamani Jesudasan, Dayalan Nadesan, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232PY2010PTC002426
- Company No.
002426
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2010
- Date of AGM
25 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pondicherry
Industry
Company Details
- Location
Villupuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Medzone Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rathina Balasubramanian  | Director | 07-Apr-2010 | Current |
| Chandra Gnanatilakan | Director | 11-Mar-2010 | Current |
| Deivasigamani Jesudasan | Director | 11-Mar-2010 | Current |
| Dayalan Nadesan | Director | 07-Apr-2010 | Current |
Abdul Shamshudeen  | Director | 27-Jun-2010 | Current |
Financial Performance and Corporate Structure Insights of Medzone Pharmaceuticals.
Medzone Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 18.08% decrease. The company also saw a substantial improvement in profitability, with a 16.92% increase in profit. The company's net worth dipped by a decrease of 4.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medzone Pharmaceuticals?
In 2017, Medzone Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
30 years 4 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 18 Mar 2022 | ₹0.78 M | Open |
Indian Overseas Bank Creation Date: 11 Mar 2011 | ₹5.00 M | Open |
How Many Employees Work at Medzone Pharmaceuticals?
Medzone Pharmaceuticals has a workforce of 9 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Mar 21, 2011, Medzone Pharmaceuticals has raised a total of ₹ 0.3 M, with the most recent deal valued at ₹ 0.3 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
